Cencora's Specialty Engine Powers a Reacceleration and Raised Guidance

Strong Q3 with 12% EPS growth, MSO strength, and Part B biosimilar opportunity position the distributor for a durable fiscal 2027.

ABC · Earnings Call · 2026-08-05

A Beat on Execution, Not Just Guidance

Cencora (ABC) delivered a decisive third quarter, with adjusted operating income up 17% and adjusted EPS up 12%, underpinned by $1 billion of opportunistic buybacks. As new CFO Eva Boratto framed it in her prepared remarks, “Adjusted operating income grew 17%, driven by strong execution in our U.S. Healthcare Solutions segment including the performance of our OneOncology acquisition and continued growth in our International segment.” — Eva Boratto, Executive (exact title not specified, likely senior executive or similar) · 2026-08-05 The company raised its full‑year EPS guidance to $17.75–$17.95, signaling confidence that the momentum is not a one‑off. This is exactly the kind of earnings growth that has been a top global theme in recent quarters—and Cencora is now delivering it with tangible acceleration.

The Reacceleration in U.S. Healthcare: Specialty and MSOs Lead

The most striking development was the rebound in U.S. Healthcare Solutions operating income growth—from 7% last quarter to double digits this quarter, excluding the lost oncology customer and OneOncology's contribution. “Excluding the loss, as you said, of Florida Cancer and the contribution from OneOncology, our operating income growth was up double digits, a meaningful acceleration from the 7% last quarter.” — Eva Boratto, Executive (exact title not specified, likely senior executive or similar) · 2026-08-05 The strength is concentrated in the company's management services organizations (MSOs), particularly OneOncology and RCA, which are outperforming expectations. Bob Mauch elaborated on the three‑phase value creation thesis—integration, capability sharing, and new service development—and noted that the clinical trial opportunity, particularly in oncology, is still in early innings. This is a critical differentiator: the company is not just a distribution play but a growing platform for specialty care management, which directly supports the biosimilar pipeline and the broader shift toward community‑based care.

In Part D, it's less so because we provide less services, less wraparound services in the part D space when a product goes from an innovator brand to a biosimilar. For Part B, it's much more important... there's a larger profit opportunity because we play a bigger role.
Robert Mauch, President and CEO · 2026-08-05

The Part B biosimilar opportunity is a clear strategic focus, as it leverages the company's deep relationships with community physicians and its MSO infrastructure. This is in stark contrast to the many companies in the recent earnings cohort that are fixated on tariff refunds—a theme Cencora notably did not mention. While the market grapples with IEEPA tariff refund dynamics, Cencora is doubling down on its pharmaceutical‑centric strategy, which is likely to be more durable.

GLP‑1s and Demand Forecasting: Tapping into Secular Tailwinds

GLP‑1 sales continue to be a significant growth driver, up $2.3 billion year‑over‑year (25% growth), roughly in line with expectations. The company is also leveraging AI in demand forecasting to optimize inventory and service levels, a digital transformation that should improve margins over time. Management explicitly linked GLP‑1 strength to broader patient access, and the company is well positioned to capture the patients with obesity trend, which remains a dominant health‑care theme. The combination of these secular drivers with the MSO momentum gives Cencora a multi‑engine growth story.

Look Ahead: Fiscal 2027 and the MWI/Covetrus Merger

Eva Boratto provided initial fiscal 2027 modeling context, flagging a potential $0.35 EPS headwind from the MWI Animal Health–Covetrus merger if it closes mid‑year. She also emphasized disciplined capital deployment: internal investments, strategic M&A, opportunistic buybacks, and a growing dividend. The company is executing on its stated priorities, and the raised guidance for fiscal 2026—with U.S. operating income growth expected in the 14.5%–15.5% range—suggests the reacceleration is sustainable. In summary, Cencora is not just reporting a good quarter; it is demonstrating that its specialty and MSO strategy is translating into durable, double‑digit profit growth. The company is riding the global earnings growth theme while carving out a differentiated position in specialty care. With a new CFO, a clear capital allocation framework, and a pipeline of growth initiatives, the stock remains compelling for investors seeking health‑care services exposure.